Resumen de Chordoma: demographics and survival analysis with a focus on racial disparities and the role of surgery, a U.S. population-based study
Asad Ullah, Guirshney Samarah Kenol, Kue Tylor Lee, Abdul Qahar Khan Yasinzai, Abdul Waheed, Bina Asif, Imran Khan, Hajra Sharif, Jaffar Khan, Saleh Heneidi, Nabin R. Karki, Tamour Khan Tareen
Background Chordoma is a rare malignant tumor of notochordal origin that may appear anywhere in the axial skeleton from the skull base to the sacrum. This study presents findings from a large database query to highlight the demographic, clinical, and pathological factors, prognosis, and survival of chordomas.
Methods The Surveillance, Epidemiology, and End Results (SEER) data based was used to identify patients with a “chordoma” diagnosis from 200 to 2018.
Results In a total of 1600 cases, the mean age at diagnosis was 54.47 years (standard deviation, SD ± 19.62 years). Most cases were male (57.1%) and white (84.5%). Tumor size was found to be > 4 cm in 26% of cases. Histologically, 33% with known features had well-differentiated Grade I tumors, and 50.2% of the tumors were localized. Metastasis at the time of to the bone, liver, and lung was observed at a rate of 0.5%, 0.1%, and 0.7%, respectively. The most common treatment received was surgical resection (41.3%). The overall 5-year overall survival observed was 39% (confidence interval, CI 95% 37–41; p = 0.05) with patients who received surgery having a 5-year survival rate of 43% (CI 95% 40–46; p = 0.05). Multivariate analysis showed independent factors that contributed to worse prognosis chemotherapy only as a treatment modality and no surgery as a treatment modality.
Conclusion Chordomas are more common in white males and appear between the 5th and 6th decades of life. Factors that contributed to a worse prognosis were Asian, Pacific Islander, American Indian, or Alaska Native races.
